Polyphenols Plus Exercise: Small Gains in Glucose Control

Adding polyphenols to an exercise program may lower fasting glucose and insulin a little more than exercise alone in previously untrained adults. The first meta-analysis on the pairing found a mean fasting-glucose difference of −0.17 mmol/L—about −3.1 mg/dL—with a 95% confidence interval (CI) of −0.32 to −0.02 mmol/L. Fasting insulin fell by −14.43 pmol/L (95% CI, −24.98 to −3.87) [about 2.1–2.4 mIU/L, depending on the conversion convention]. Both results were statistically significant.

That is a real signal, but it is not a metabolic makeover. A 3.1 mg/dL change in fasting glucose would not move someone with prediabetes below a standard diagnostic cutoff. The same analysis found no added advantage for blood pressure, body weight, waist circumference, body fat, total cholesterol, LDL-C, HDL-C, C-reactive protein, or IL-6. The combination may be a modest add-on for glucose metabolism, not a reason to expect better results everywhere.

What the pooled trial evidence found

Amoah et al.'s 2026 systematic review and meta-analysis compared dietary polyphenols plus exercise—often shortened to ExPo—with exercise alone or polyphenols alone in untrained adults. The review was registered in PROSPERO (CRD42024508608) and examined a broad cardiometabolic panel.

Against exercise-only control arms, ExPo produced the two statistically significant differences that matter most to this story: fasting glucose fell by −0.17 mmol/L (95% CI, −0.32 to −0.02), and fasting insulin fell by −14.43 pmol/L (95% CI, −24.98 to −3.87). Using 6.0 pmol/L per mIU/L, the insulin difference equals about −2.4 mIU/L; using 6.945 pmol/L per mIU/L, it equals about −2.1 mIU/L.

Against polyphenol-only control arms, ExPo was associated with a −0.18 mmol/L triglyceride difference, but its 95% CI ran from −0.37 to exactly 0.00 mmol/L. That result sits on the statistical boundary. It should be treated as uncertain rather than as a confirmed lipid benefit.

The review authors described the overall improvement as limited. Their conclusion fits the endpoint pattern: a small glycemic advantage over exercise alone, a fragile triglyceride finding versus polyphenols alone, and null results across the rest of the measured panel.

Statistical significance does not settle clinical value

The glucose result cleared a conventional statistical threshold, meaning the pooled estimate was unlikely to arise from chance alone under the model used. It does not show that the change prevents diabetes, cardiovascular events, or other clinical outcomes. The study measured fasting biomarkers, not disease incidence or patient-important outcomes.

Absolute size matters here. A mean reduction of 0.17 mmol/L is roughly 3.1 mg/dL. For a person with fasting glucose of 105 mg/dL, that average shift would land near 102 mg/dL, still within the prediabetes range. People vary, of course, but the pooled mean does not justify calling the combination a primary metabolic treatment.

The insulin estimate also deserves restraint. Its CI spans 21.11 pmol/L, from −24.98 to −3.87 pmol/L. The benefit could be modest or somewhat larger, and the available publication details do not let readers assess how many trials or participants shaped that uncertainty. The abstract does not report the number of included randomized trials, per-arm sample sizes, intervention durations, or heterogeneity statistics such as I².

Which polyphenol and which exercise program?

The pooled analysis does not provide subgroup results by polyphenol class, dose, bioavailability format, or exercise modality. That omission matters because "polyphenols" covers a very large family of compounds, while "exercise" can mean anything from steady aerobic training to resistance work or HIIT. A capsule of green-tea catechins and a food-based anthocyanin intervention should not be presumed interchangeable.

One directly relevant randomized trial helps explain why the pooled signal may not apply evenly. Sukatta et al. (2025) studied a microencapsulated blend containing quercetin, ferulic acid, chlorogenic acid, and cyanidin-3-glucoside alongside concurrent aerobic and resistance training. In adults with overweight or obesity and prediabetes, the combination improved metabolic and inflammatory markers versus comparators. This is useful support for the glucose-and-insulin finding, but it is one trial in a higher-risk population using a specialized delivery format. It cannot identify the best supplement for metabolically healthy beginners.

Polyphenols alone can also affect insulin-related outcomes in selected populations. Basu et al. (2025) reported improved insulin resistance and related cardiometabolic markers in a randomized crossover trial of strawberries in adults with prediabetes. In another randomized controlled trial, Pett et al. (2025) found increased insulin sensitivity after four weeks of mango intake in 48 adults with overweight or obesity and chronic low-grade inflammation. Neither study proves that a supplement-plus-training stack will outperform either component in every population. They do show that food-derived polyphenols can have context-dependent effects without an exercise co-intervention.

Why the studies do not point to one universal stack

Results differ across compounds, populations, and background activity. Roberts et al. (2021) tested decaffeinated green-tea extract providing at least 270 mg EGCG per day with exercise in overweight adults who were already recreationally active. The trial found limited cardiometabolic effects. That population had more baseline activity than the untrained group targeted by the meta-analysis, and it used a different polyphenol exposure. Those differences can change both the room for improvement and the biological response.

Animal work offers a possible mechanism, not clinical proof. In fructose-induced metabolic syndrome rats, Er et al. (2022) found protective metabolic effects from exercise plus quercetin. Quercetin may complement exercise-related glucose transport and anti-inflammatory pathways, but rat dosing and a fructose-fed disease model cannot tell us whether a human supplement produces a meaningful cardiometabolic outcome.

Exercise itself remains the intervention with the broadest case for cardiometabolic health. Reviews of exercise training in adults with overweight or obesity and of low-volume HIIT report improvements in glycemic control and cardiovascular risk factors, although the available results do not provide directly comparable pooled mean differences for a clean three-way calculation. The 2025 exercise-training review and the 2025 low-volume HIIT meta-analysis support exercise as a foundation; they do not establish that ExPo adds a clinically meaningful amount beyond it.

What to do with this evidence

If you are sedentary and have insulin resistance or elevated metabolic risk, regular training deserves your attention before any polyphenol stack. Adding a polyphenol-rich food or supplement may offer a small incremental glucose-and-insulin benefit, especially in a higher-risk phenotype, but the present evidence cannot name the compound, dose, delivery system, or training format responsible for the pooled effect.

• Expect a small possible change in fasting glucose and insulin, not weight loss or a blood-pressure effect.
• Do not treat the triglyceride result as established; its CI touches zero.
• Choose foods with polyphenols for their overall dietary value rather than assuming every extract has the same effect.
• Keep exercise, sleep, dietary pattern, and energy intake ahead of supplements in the hierarchy of metabolic interventions.

The honest verdict: polyphenols may slightly augment exercise-related glucose control in untrained adults, but the evidence does not support a universal "synergy" claim or a specific supplement recommendation.